Esperion's cholesterol drug succeeds in late-stage study


REUTERS: Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease. Esperion is looking to target patients who are unable to take or do not show improvement with statins, a class of medicines that lower the level of low-density lipoprotein cholesterol in the blood.



from Biotech News